Amgen Inc at BMO Capital Markets Prescription for Success Healthcare Conference (Virtual) Transcript
Good afternoon. My name is Do Kim. I'm one of the biotech analysts here at BMO. For our next presentation and fireside chat, we're happy to have with us, Elliott Levy, Senior Vice President of R&D Strategy and Operations; and Arvind Sood, Head of IR at Amgen. Start maybe, Elliott, you could have some opening comments and talk to Amgen's priority for clinical development.
Great. Thanks for giving me the opportunity to speak today. At Amgen, our focus is on development of first-in-class therapies in areas of high unmet medical need. We look for areas where we can bring value based on our established capabilities in protein discovery and development, in immunology, and unique platforms like our BiTE platform. And we focus on 3 therapeutic areas: hematology, oncology, inflammation and cardiovascular disease.
We have a number of key data readouts later this year. These include our potentially pivotal study with AMG 510 or
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
